Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.pupt.2014.03.002 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Shining a spotlight on pulmonary hypertension associated with interstitial lung disease care: The latest advances in diagnosis and treatment.
J Manag Care Spec Pharm
January 2025
PRIME Education, New York City, NY.
Pulmonary hypertension associated with interstitial lung disease (PH-ILD) is a complex condition in which 2 consequential diseases interact and increase negative outcomes. Although the pathophysiologic mechanisms of PH-ILD are not yet well understood, the pronounced effect on functional status, supplemental oxygen requirements, health care resource utilization, and mortality that frequently accompany this diagnosis are well documented. A critical feature that complicates pathophysiologic understanding of PH-ILD is that progression of the pulmonary vascular disease does not always appear to be driven by the underlying lung disease.
View Article and Find Full Text PDFEnhanced vasoconstriction in sickle cell disease is dependent on ETA receptor activation.
Clin Sci (Lond)
December 2024
Section of Cardiorenal Physiology & Medicine, Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL 35233, U.S.A.
Article Synopsis
- * In research using mice, SCD was found to enhance vasoconstriction (narrowing of blood vessels) through the alpha-1 adrenergic receptor, particularly by increasing the expression of the alpha-1a receptor in the aortic tissue of SCD mice compared to controls.
- * Treatment with ambrisentan, an ETA receptor blocker, improved blood vessel function in both mice and SCD patients, suggesting that targeting the ET-1 pathway could help improve vascular health in individuals with
Liver injury associated with endothelin receptor antagonists: a pharmacovigilance study based on FDA adverse event reporting system data.
Int J Clin Pharm
December 2024
West China School of Pharmacy, Sichuan University, Chengdu, Sichuan, China.
Background: Endothelin receptor antagonists are commonly used in clinical practice, with concerns about their hepatotoxicity.
Aim: This study aimed to conduct a comprehensive pharmacovigilance study based on FDA adverse event reporting system data to evaluate the possible association between endothelin receptor antagonists and drug-induced liver injury.
Method: Adverse event reports from FDA adverse event reporting system between January 2004 and December 2022 were analyzed.
Identification of EDNRA as the Key Biomarker for Hypercholesterolemia and Colorectal Cancer.
Tohoku J Exp Med
March 2024
Department of Oncology, Maoming People's Hospital.
Some studies have investigated the role of cholesterol in the progression of colorectal cancer (CRC). However, the underlying mechanism of action is not clear. In this study, we used bioinformatics tools to elucidate the molecular mechanisms involved.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!